Skip to main
BNTX

BioNTech SE (BNTX) Stock Forecast & Price Target

BioNTech SE (BNTX) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 46%
Buy 31%
Hold 23%
Sell 0%
Strong Sell 0%

Bulls say

BioNTech is a promising biotechnology company with a strong focus on developing innovative cancer therapies and vaccines, including their commercially successful covid vaccine Comirnaty. The company has a diverse and robust oncology pipeline, with several promising drug candidates, including mRNA-based drugs, antibodies, and ADCs. Additionally, the partnership with Pfizer and the upcoming launch of new products provide positive short-term catalysts for the company. However, potential risks include slower market uptake, regulatory challenges, and potential dilution risks in the long term.

Bears say

BioNTech is facing significant commercial and partnership risks, as their oncology pipeline may not be able to generate the forecasted revenues due to safety and efficacy concerns, potential competition from more efficacious treatments, and potential delays in regulatory approval. This is further compounded by the company's increased reliance on their COVID vaccine, which is expected to see a decline in revenue. Additionally, the departure of the co-founders and leadership transition may introduce further uncertainty and impact investor confidence in the company's future prospects.

BioNTech SE (BNTX) has been analyzed by 13 analysts, with a consensus rating of Buy. 46% of analysts recommend a Strong Buy, 31% recommend Buy, 23% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BioNTech SE and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BioNTech SE (BNTX) Forecast

Analysts have given BioNTech SE (BNTX) a Buy based on their latest research and market trends.

According to 13 analysts, BioNTech SE (BNTX) has a Buy consensus rating as of Aug 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $127.31, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $127.31, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BioNTech SE (BNTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.